Stocks - Gilead Soars in Premarket on Remdesivir Update

Stocks - Gilead Soars in Premarket on Remdesivir Update

Apr 29, 2020

By Geoffrey Smith 

- Stocks in focus in premarket trade on Wednesday, 29th April. Please refresh for updates.

  • Gilead Sciences (NASDAQ:GILD) stock rose 9.5% in premarket after it said that it was aware of “positive data” from the trial of its experimental drug remdesivir with regard to treating the Covid-19 virus.
  • The NIAID will brief later on its findings.
  • Boeing (NYSE:BA) stock was up 5.2% after Reuters reported it intends to cut roughly 10% of its workforce as it brings production into line with a much lower level of demand from airlines.  The company will also cut production of its 787 Dreamliner further.
  • Boeing lost $1.7 billion in the first quarter, more than expectations, while revenue also fell by more than expected.
  • General Electric (NYSE:GE) stock fell 1.6% after its first-quarter earnings fell short of expectation, with the Covid-19 virus hitting its aviation business particularly badly.
  • GE had bet heavily on aviation and health care rescuing it from its chronic profitability problems.
  • Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG) stock was up 8.2% after better-than-expected results for the first quarter that showed its Internet advertising business holding up well despite the pandemic.
  • Advanced Micro Devices (NASDAQ:AMD) stock was down 2.0% after the company cut its forecasts for the year, expecting a sharp slowdown in business investment.
  • AMD lowered the bottom end of its guidance for sales growth to 20% from 28% previously. It still expects an adjusted gross margin of 45%.

Join Libertex!

Practice for free on a demo account with 50,000 euro

Register
or start live trading now